Thyroid Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against thyroid cancer and guarantee the finest results for our customers all over the world.

Thyroid Cancer

Thyroid cancer is a cancer that develops from thyroid tissue. It's a condition where cells grow abnormally and have the potential to spread to other parts of the body. There are four main types - follicular thyroid carcinoma, papillary thyroid carcinoma, anaplastic thyroid carcinoma and medullary thyroid carcinoma. Symptoms may include swelling or a lump in the neck. Risk factors include goiter, family history and radiation exposure at a young age. Diagnosis is usually based on ultrasound and fine needle aspiration. Treatment options may include surgery, thyroid hormones, radiotherapy including radioactive iodine, chemotherapy, and targeted therapies.

Most forms of thyroid cancer have a good prognosis. Some tumors, however, dedifferentiate and may finally develop into highly malignant anaplastic thyroid carcinomas with a low survival time. Due to their dedifferentiation, these tumors are inaccessible to classical therapeutic options as radioiodide treatment or thyrotropin-suppression. During the past few years, new developments in immunology have revealed increasing information about the molecular basis of tumor-host interactions. The multitude of information resulting from basic science in cellular immunology, together with the availability of biologic reagents in pharmacological amounts, has opened new venues for the development of immunotherapy approaches for patients with different kind of cancers including thyroid malignancies.

Therapeutic Vaccines for Thyroid Cancer

Vaccination with calcitonin and/or CEA peptide-pulsed DC results in the induction of a cellular, antigen-specific immune response in patients with MTC, leading to clinical response in some patients. Recent studies suggest that immunization with autologous dendritic cells (DCs) pulsed with tumor antigen result in protective immunity and rejection of established tumors in various human malignancies. ADC vaccination therapy was developed in patients with metastasized medullary thyroid carcinoma (MTC). Mature DCs were generated from peripheral blood monocytes in the presence of granulocyte macrophage colony-stimulating factor, IL-4, and TNFα. After loading with calcitonin and carcinoembryonic antigen (CEA) peptide, DCs were repeatedly delivered by sc injections. During follow-up, all patients developed a strong delayed-type hypersensitivity skin reaction caused by perivascular and epidermal infiltration with CD4⁺ memory T cells and CD8⁺ cytotoxic T cells.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the thyroid cancer vaccines. If you are interested in our services, please contact us for more details.

Reference

1. Schott, M. (2001). “Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.” J Clin Endocrinol Metab 86(10), 4965-4969.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.